Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes

 

London Men’s Clinic urologists Mr Alnajjar and Prof Muneer are pleased to share their latest publication with collaborators Radion Garaz and Constantine Alifrangis, in European Urology Focus on Systemic Therapies for Penile Cancer. 

 

Background and Objective

 

Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting.

 

Conclusions and Clinical Implications

 

No standard systemic therapy exists beyond first-line treatment for metastatic or recurrent PSCC. Targeted agents and immune checkpoint inhibitors show encouraging activity in biomarker-selected subgroups. Prospective biomarker-guided trials and international collaborations are needed, while multidisciplinary management and clinical trial enrollment remain essential for optimizing outcomes for this rare malignancy.

 

You can access the full article here.

 

Citation:

Garaz, M. Ziada, J. Crozier et al., Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes, Eur Urol Focus (2026)

 

#PenileCancer #MaleGenitalCancer #Andrology #Immunotherapy #TargetedTherapy #Chemotherapy